Goldman Sachs Group Inc Affimed N.V. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.32 - $0.62 $9,141 - $17,712	-28,568 Reduced 51.15%	27,278 $16,000
Q3 2023 May 14, 2024	BUY	$0.46 - $0.65 $13,141 - $18,569	28,568 Added 104.73%	55,846 $26,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $115,866 - $163,723	-251,883 Reduced 81.85%	55,846 $26,000
Q2 2023 May 14, 2024	BUY	$0.57 - $1.08 $27,461 - $52,032	48,178 Added 18.56%	307,729 $184,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $27,461 - $52,032	48,178 Added 18.56%	307,729 $184,000
Q1 2023 May 14, 2024	SELL	$0.66 - $1.29 $433,254 - $846,815	-656,446 Reduced 71.66%	259,551 $194,000
Q1 2023 May 11, 2023	SELL	$0.66 - $1.29 $433,254 - $846,815	-656,446 Reduced 71.66%	259,551 $194,000
Q4 2022 May 14, 2024	SELL	$1.1 - $2.45 $381,399 - $849,481	-346,727 Reduced 27.46%	915,997 $1.14 Million
Q4 2022 Feb 13, 2023	SELL	$1.1 - $2.45 $381,399 - $849,481	-346,727 Reduced 27.46%	915,997 $1.14 Million
Q3 2022 May 14, 2024	BUY	$1.96 - $3.32 $1.37 Million - $2.33 Million	700,851 Added 124.73%	1,262,724 $2.6 Million
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $1.37 Million - $2.33 Million	700,851 Added 124.73%	1,262,724 $2.6 Million
Q2 2022 May 14, 2024	BUY	$2.27 - $4.86 $1.21 Million - $2.6 Million	534,595 Added 1959.8%	561,873 $1.56 Million
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $1.14 Million - $2.43 Million	-500,306 Reduced 47.1%	561,873 $1.56 Million
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $1.89 Million - $2.89 Million	-512,121 Reduced 32.53%	1,062,179 $4.64 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $6.83 Million - $8.99 Million	-1,271,900 Reduced 44.69%	1,574,300 $8.69 Million
Q3 2021 Nov 10, 2021	BUY	$5.54 - $7.51 $15.8 Million - $21.4 Million	2,846,200 New	2,846,200 $17.6 Million

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account